Evidence map›Paper›PMID 26473150›Full record

ArticleProstate international2015

Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer.

Atsushi Ikeda, Toru Nakagawa, Koji Kawai, Mizuki Onozawa, Takeshi Hayashi, Yumi Matsushita, Masakazu Tsutsumi, Takahiro Kojima, Jun Miyazaki, Hiroyuki Nishiyama

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk.International journal of molecular sciences · 2019
    Review
  5. Article
  6. Article
  7. Role of Adiponectin in prostate cancer.International braz j urol : official journal of the Brazilian Society of Urology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Atsushi IkedaDepartment of Urology, Hitachi General Hospital, Ibaraki, Japan ; Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Toru NakagawaHitachi Health Care Center, Hitachi Ltd., Ibaraki, Japan.
Koji KawaiDepartment of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Mizuki OnozawaDepartment of Urology, Tokyo-kita Medical Center, Tokyo, Japan.
Takeshi HayashiHitachi Health Care Center, Hitachi Ltd., Ibaraki, Japan.
Yumi MatsushitaDepartment of Clinical Research, National Center for Global Health and Medicine, Tokyo, Japan.
Masakazu TsutsumiDepartment of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Takahiro KojimaDepartment of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Jun MiyazakiDepartment of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Hiroyuki NishiyamaDepartment of Urology, Hitachi General Hospital, Ibaraki, Japan.
University of Tsukuba · JPHitachi (Japan) · JPHitachi General Hospital · JPNational Center for Global Health and Medicine · JPTokyo-Kita Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent investigations suggest that serum adiponectin levels are negatively associated with the development of aggressive prostate cancer, however, not all epigenetic studies support the inverse association.

methodsWe analyzed serum adiponectin levels, prostate-specific antigen (PSA) levels, and outcomes of prostate cancer screening of 2,939 participants of a PSA-based screening program conducted by a single institute in Japan.

resultsThe median body mass index (BMI) of the participants was 23.9 kg/m(2), and 31% had a BMI ≥ 25 kg/m(2). The adiponectin levels were significantly and negatively correlated with BMI (r =  -0.260, P < 0.0001). However, a significant and positive correlation was observed between adiponectin levels and PSA levels (r = 0.054, P = 0.0061). After screening, 24 (0.82%) patients were diagnosed with prostate cancer. Interestingly, the adiponectin levels of the 24 prostate cancer patients (average 9.86 μg/mL) were significantly higher than those of the 2,817 participants with PSA levels < 4 ng/mL (average 7.63 μg/mL) (P = 0.0049). However, when restricted to the eight high-risk prostate cancer patients, the adiponectin levels did not differ from those of the participants with PSA levels < 4 ng/mL. The age-adjusted cancer detection rate of the participants was calculated by stratifying the BMI (cut-off level 25 kg/m(2)) and adiponectin levels (cut-off level 6.7 μg/mL). The cancer detection rate in the high-BMI and high-adiponectin group was 1.67%, which was the highest among all groups.

conclusionsThere was a significant positive correlation between adiponectin levels and PSA levels. The present findings also suggest that the incidence of low- or intermediate-risk prostate cancer might be increased in overweight men with high serum adiponectin levels.

Indexed as

AdiponectinBody mass indexProstate cancerProstate-specific antigenScreening

Identifiers

PMID26473150
PMCPMC4588391
OpenAlexW1894814330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.